Idorsia Ltd (IDIA) fair value: what the stock is really worth
We calculate from audited financials what Idorsia Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Sep 20, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Idorsia Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 20, 2026.
How to read this chart
60‑month range CHF 0.6325 – CHF 25.52 · fair‑value band CHF 6.85 – CHF 14.53 · the CHF 4.44 price screens below the CHF 11.32 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 20, 2026.
Follow Idorsia in your weekly email
Every Wednesday you see whether Idorsia is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases.
Show more
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Stock analysis
Idorsia Ltd (IDIA) currently trades at CHF 4.44, while our model-based Fair Value estimate is CHF 11.32, implying the stock looks roughly 60.8% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: CHF 6.85 (bear) to CHF 14.53 (bull), the price of CHF 4.44 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Idorsia Ltd reported revenue of CHF 221M in FY2025 versus CHF 35.3M in FY2021, a compound +58.1%/yr. Reported net income was −CHF 112M in FY2025.
Key figures
Market cap CHF 1.5B · P/S ratio 7.00 · EPS (TTM) CHF −1.03 · Net margin −50.7% · Return on equity −6,461% · Return on assets (EBIT) −51.0% · Operating margin −46.2% · Revenue (TTM) CHF 219M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 52% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 155%, IDIA screens cheaper than that median.
Notify me when IDIA reaches fair value
Put IDIA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+96.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
’17
’18
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−572.2% (2020) → −59.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 648 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score38 · Below median
Fair Value upside+155.0% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−16.1% · Below median
Net margin (TTM)−100.7% · Bottom 25%
Operating margin (TTM)−46.2% · Bottom 25%
Growth and dividend
Revenue growth−2.5% · Below median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)8.45× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 24
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Idorsia Ltd Fair Value". https://www.fairvalue-calculator.com/stock/IDIA
Frequently asked questions
Is Idorsia Ltd (IDIA) overvalued or undervalued?
As of Sep 20, 2026, our model estimates a fair value of CHF 11.32 versus a price of CHF 4.44, about +155% upside (undervalued).
What is the fair value of IDIA?
Our model-based fair value for Idorsia Ltd is CHF 11.32 (as of Sep 20, 2026), built from audited fundamentals. The current price: CHF 4.44.
What is the quality score of IDIA?
Idorsia Ltd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Idorsia Ltd (IDIA)?
Our model-based price target is the fair value of CHF 11.32 (as of Sep 20, 2026) from 2 valuation models. Cautious scenario CHF 6.85, optimistic scenario CHF 14.53. It is a calculation from audited fundamentals, not an analyst target.
What is the Idorsia Ltd stock forecast for 2026?
Our models put fair value at CHF 11.32, about +155% upside versus a price of CHF 4.44 (undervalued). Cautious scenario CHF 6.85, optimistic scenario CHF 14.53. The calculation is refreshed regularly with new filings.
What is the revenue of Idorsia Ltd (IDIA)?
Idorsia Ltd reported trailing-twelve-month revenue of about CHF 219M (latest available figure, as of Sep 20, 2026).
What is the intrinsic value of Idorsia Ltd (IDIA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Idorsia Ltd it is CHF 11.32 per share (as of Sep 20, 2026), against a price of CHF 4.44. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Idorsia Ltd stock overvalued or undervalued in 2026?
As of Sep 20, 2026, IDIA trades below its calculated fair value: price CHF 4.44, fair value CHF 11.32, a gap of about +155% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IDIA?
No. The price is what the market pays today (CHF 4.44); the fair value is what the company's own numbers justify (CHF 11.32). For Idorsia Ltd the two are CHF 6.88 per share apart. That gap is exactly why we show both numbers side by side.
How much is Idorsia Ltd worth?
The market values Idorsia Ltd at about CHF 1.5B (market capitalisation, as of Sep 20, 2026). Per share that is CHF 4.44; our models calculate a fair value of CHF 11.32 per share.
What do the bullish and bearish scenarios say about IDIA?
Our models span a range for Idorsia Ltd: cautious scenario CHF 6.85, base CHF 11.32, optimistic CHF 14.53 per share (as of Sep 20, 2026, price CHF 4.44). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Idorsia Ltd (IDIA)?
Balance-sheet figures for Idorsia Ltd (as of Sep 20, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is IDIA from its 52-week high?
Idorsia Ltd trades at CHF 4.44, about 36% below its 52-week high of CHF 6.89 and 52% above the low of CHF 2.93 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 11.32 is for.
Which stocks are comparable to Idorsia Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Idorsia Ltd stock attractive at the current price?
The data as of Sep 20, 2026: price CHF 4.44, calculated fair value CHF 11.32 (+155%), Quality Score 39/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IDIA calculated?
We run Idorsia Ltd through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 11.32, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Idorsia Ltd currently trades 155 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Idorsia Ltd (IDIA)?
The closing price on Sep 25, 2026 was CHF 4.44. Our model-based fair value is CHF 11.32, about +155% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Idorsia Ltd right now?
The large discount to fair value meets weak quality (39/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (CHF 6.85). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (CHF 6.85 to CHF 14.53) leaves room in how you read the outcome.
Key figures of Idorsia Ltd
How large is the market capitalisation of Idorsia Ltd (IDIA)?
The market capitalisation of Idorsia Ltd is CHF 1.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Idorsia Ltd (IDIA)?
The price-to-sales ratio of Idorsia Ltd is 7.00 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Idorsia Ltd (IDIA)?
Earnings per share at Idorsia Ltd are CHF −1.03. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Idorsia Ltd (IDIA)?
The net margin of Idorsia Ltd is −50.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Idorsia Ltd (IDIA)?
The return on equity (ROE) of Idorsia Ltd is −6,461% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Idorsia Ltd (IDIA)?
On an EBIT basis the return on assets of Idorsia Ltd is −51.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Idorsia Ltd (IDIA)?
The operating margin of Idorsia Ltd is −46.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Idorsia Ltd (IDIA)?
Revenue at Idorsia Ltd is growing −2.5% versus a year earlier (3y avg +31.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Idorsia Ltd (IDIA)?
Earnings per share at Idorsia Ltd are growing +76.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Idorsia Ltd (IDIA) generate?
The free cash flow of Idorsia Ltd is −CHF 167M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Idorsia Ltd (IDIA) carry?
The net debt of Idorsia Ltd is CHF 1.2B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Idorsia Ltd in the live analysis
One click puts Idorsia Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
